Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study.
The aim of this study was to assess the efficacy and toxicity of an idarubicin-prednimustine combination in advanced breast cancer. 19 patients received idarubicin 35 mg/m2 day 1 and prednimustine 100 mg/m2 days 2-6, every 21 days. Three objective responses with a median duration of 7 months were observed. Tolerance was good. A further 23 patients were given idarubicin administered at 15 mg/m2 days 1, 2 and 3 and prednimustine at the aforementioned dosage. 8 (35%) showed an objective response (4 CRs, 4 PRs) with a median duration of 6 months. No severe toxicity was observed. Results suggest activity of idarubicin-prednimustine combinations in advanced breast cancer, and further studies are indicated since this regimen is easily administered, especially to elderly patients.
Barnadas
A
A
Department of Medical Oncology, Hospital Germans Trias y Pujol, Badalona, Spain.
Mendiola
C
C
Casado
A
A
Villar
A
A
Jimeno
J
J
Clerigue
M
M
Rosell
R
R
Diaz-Rubio
E
E
Cortés-Funes
H
H
García de Paredes
M
M
D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011238:Prednimustine / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D011238:Prednimustine; D015255:Idarubicin